Positive statement on phase 2 tox22 Jun 2026 09:59
I like the confirmation that Phase 2 tox is well underway
"These biomarker findings are predictive of SDC-1801's potential efficacy in patients and reinforce our confidence in SDC-1801's potential as a differentiated therapy for autoimmune diseases. With the Phase 2-enabling toxicology programme well underway, we are focused on translating this clinical evidence into the next stage of development."